On March 31, 2022, James Pennington, M.D., Chief Medical Officer of First Wave BioPharma, Inc. (the 'Company'), informed the Company of his intention to retire as Chief Medical Officer. Dr. Pennington's notice did not relate to any disagreement with the operations, policies or practices of the Company on any matters. Dr. Pennington will transition to a consultant role until a new Chief Medical Officer has been appointed.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.7 USD | +2.66% | +5.06% | -35.71% |
05-20 | Entero Therapeutics, Inc.(NasdaqCM:ENTO) added to NASDAQ Composite Index | CI |
05-17 | First Wave BioPharma, Inc. will Change its Name to Entero Therapeutics, Inc | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.71% | 6.05M | |
+43.36% | 58.06B | |
-5.31% | 40.53B | |
+37.52% | 38.99B | |
+14.75% | 26.7B | |
-12.56% | 26.56B | |
-22.45% | 18.98B | |
+0.04% | 12.17B | |
+25.12% | 12B | |
+26.04% | 11.92B |
- Stock Market
- Equities
- ENTO Stock
- News Entero Therapeutics, Inc.
- James Pennington Announces His Intention to Retire as Chief Medical Officer of First Wave BioPharma, Inc